The Brazil Pancreatic Cancer Therapeutics market size stood at around USD xx million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Pancreatic cancer begins in the tissues of your pancreas — an organ in your abdomen that lies behind the lower part of your stomach. Your pancreas releases enzymes that aid digestion and produces hormones that help manage your blood sugar. Pancreatic cancer is seldom detected at its early stages when it’s most curable. This is because it often doesn’t cause symptoms until after it has spread to other organs.
Pancreatic cancer treatment options are chosen based on the extent of the cancer. Options may include surgery, chemotherapy, radiation therapy or a combination of these.
The increasing pervasiveness of pancreatic cancer and significant incidence of pancreatic cancer initiates germline mutations is fuelling up the demand of the market. The growing demand for targeted therapy is another factor propelling the growth of the pancreatic cancer therapeutics market.
In addition, high adoption of immunotherapy, rich pipeline and favourable reimbursement scenario by Brazilian healthcare system (SUS) are considered as a positive indicator for growth of pancreatic cancer treatment.
Major Pancreatic Cancer
Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. The exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.